Testing Focused Ultrasound on a Deep Brain Area in Huntington's Disease
Tests focused ultrasound for movement symptoms in adults with Huntington's disease.
Plain-language title generated from the registry record
Registry title: Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
Key facts
- Where
- Fuzhou, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07513844, who can take part
Where in China
- Department of Rehabilitation Medicine, The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Fujian Medical University
- Trial code
- NCT07513844
- Record updated
- 29 April 2026
- Original description
The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor symptoms in patients with Huntington's disease.Read full original descriptionShow less
Low-Intensity Focused Ultrasound Stimulation of the External Globus Pallidus in Huntington's Disease: A Phase I/II Safety and Feasibility Trial
The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor symptoms in patients with Huntington's disease.
Inclusion: Aged 18 to 75 years (inclusive); Genetically confirmed Huntington's disease with HTT CAG repeat length of 40 or greater; Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 8 or higher on a scale of 0 to 28, with higher scores indicating more severe chorea; Huntington's Disease Integrated Staging System stage 2 or 3; Willing to participate and provide informed consent; Have a reliable caregiver available; No severe cognitive impairment that would preclude reliable reporting of adverse events or efficacy during treatment.
Exclusion: Prior treatment with electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, or other neuromodulation therapies within the past 3 years; Concurrent participation in another interventional clinical trial; History of self-injury, aggressive behavior, or unstable psychiatric disorders; History of head injury or neurosurgical procedure; Presence of intracranial implants, metallic foreign bodies, cochlear implants, or cardiac pacemakers; Severe systemic disease, pregnancy, or breastfeeding; Any other condition that, in the opinion of the investigator, would preclude participation; Contraindications to magnetic resonance imaging, ultrasound, or anesthesia; Severe brain atrophy with unclear external globus pallidus structure on MRI.